The Zhitong Finance App learned that Yamato released a research report saying that Sinopharm Holdings (01099.HK) revenue has begun to stabilize, but there is no clear rebound schedule. The 2026 retail pharmacy revenue guidance grew by double digits year over year. The rating was downgraded from “outperforming the market” to “holding”, and the target price was lowered from HK$21 to HK$18. Earnings per share are expected to increase by 4.5%, 5.6% and 8.5% year-on-year respectively from 2026 to 2028, which is 3% to 6% lower than market expectations.

The Zhitong Finance App learned that Yamato released a research report saying that Sinopharm Holdings (01099.HK) revenue has begun to stabilize, but there is no clear rebound schedule. The 2026 retail pharmacy revenue guidance grew by double digits year over year. The rating was downgraded from “outperforming the market” to “holding”, and the target price was lowered from HK$21 to HK$18. Earnings per share are expected to increase by 4.5%, 5.6% and 8.5% year-on-year respectively from 2026 to 2028, which is 3% to 6% lower than market expectations.